A detailed history of Charles Schwab Investment Management Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 7,752,975 shares of GILD stock, worth $728 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
7,752,975
Previous 7,528,015 2.99%
Holding current value
$728 Million
Previous $516 Million 25.82%
% of portfolio
0.13%
Previous 0.1%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$66.59 - $83.99 $15 Million - $18.9 Million
224,960 Added 2.99%
7,752,975 $650 Million
Q2 2024

Aug 12, 2024

BUY
$63.15 - $72.88 $10.2 Million - $11.7 Million
160,755 Added 2.18%
7,528,015 $516 Million
Q1 2024

May 08, 2024

BUY
$71.58 - $87.29 $6.14 Million - $7.49 Million
85,771 Added 1.18%
7,367,260 $540 Million
Q4 2023

Feb 06, 2024

BUY
$73.27 - $83.09 $6.41 Million - $7.27 Million
87,482 Added 1.22%
7,281,489 $590 Million
Q3 2023

Nov 08, 2023

SELL
$73.94 - $80.67 $4.3 Million - $4.69 Million
-58,198 Reduced 0.8%
7,194,007 $539 Million
Q2 2023

Aug 09, 2023

SELL
$76.01 - $86.7 $11.4 Million - $13 Million
-149,444 Reduced 2.02%
7,252,205 $559 Million
Q1 2023

May 11, 2023

SELL
$77.31 - $88.08 $11.4 Million - $13 Million
-147,480 Reduced 1.95%
7,401,649 $614 Million
Q4 2022

Feb 13, 2023

BUY
$62.32 - $89.47 $7.9 Million - $11.3 Million
126,762 Added 1.71%
7,549,129 $648 Million
Q3 2022

Nov 14, 2022

BUY
$59.54 - $68.01 $18 Million - $20.5 Million
301,670 Added 4.24%
7,422,367 $458 Million
Q2 2022

Aug 15, 2022

SELL
$57.72 - $65.01 $7.55 Million - $8.5 Million
-130,735 Reduced 1.8%
7,120,697 $440 Million
Q1 2022

May 13, 2022

BUY
$57.92 - $72.58 $1.24 Million - $1.55 Million
21,422 Added 0.3%
7,251,432 $431 Million
Q4 2021

Feb 11, 2022

BUY
$64.88 - $73.64 $10.9 Million - $12.4 Million
168,674 Added 2.39%
7,230,010 $525 Million
Q3 2021

Nov 16, 2021

BUY
$67.69 - $73.03 $7.69 Million - $8.3 Million
113,605 Added 1.64%
7,061,336 $493 Million
Q2 2021

Aug 16, 2021

BUY
$63.47 - $69.35 $34.2 Million - $37.3 Million
538,153 Added 8.4%
6,947,731 $478 Million
Q1 2021

May 17, 2021

SELL
$60.0 - $68.46 $7.49 Million - $8.55 Million
-124,907 Reduced 1.91%
6,409,578 $414 Million
Q4 2020

Feb 16, 2021

BUY
$56.65 - $64.55 $1.07 Million - $1.22 Million
18,926 Added 0.29%
6,534,485 $381 Million
Q3 2020

Nov 13, 2020

SELL
$62.1 - $78.08 $24.3 Million - $30.5 Million
-390,755 Reduced 5.66%
6,515,559 $412 Million
Q2 2020

Aug 14, 2020

SELL
$72.34 - $84.0 $16 Million - $18.5 Million
-220,645 Reduced 3.1%
6,906,314 $531 Million
Q1 2020

May 15, 2020

BUY
$62.63 - $80.22 $5.79 Million - $7.42 Million
92,451 Added 1.31%
7,126,959 $533 Million
Q4 2019

Feb 07, 2020

BUY
$61.62 - $67.78 $6.81 Million - $7.5 Million
110,591 Added 1.6%
7,034,508 $457 Million
Q3 2019

Nov 08, 2019

BUY
$62.51 - $69.0 $9.08 Million - $10 Million
145,309 Added 2.14%
6,923,917 $439 Million
Q2 2019

Aug 09, 2019

BUY
$61.87 - $69.38 $8.13 Million - $9.12 Million
131,451 Added 1.98%
6,778,608 $458 Million
Q1 2019

May 14, 2019

BUY
$62.53 - $70.05 $37 Million - $41.5 Million
591,767 Added 9.77%
6,647,157 $432 Million
Q4 2018

Feb 14, 2019

BUY
$60.54 - $79.0 $14 Million - $18.3 Million
232,046 Added 3.98%
6,055,390 $379 Million
Q3 2018

Nov 13, 2018

BUY
$71.28 - $78.92 $25.4 Million - $28.1 Million
356,677 Added 6.52%
5,823,344 $450 Million
Q2 2018

Aug 08, 2018

BUY
$64.88 - $75.68 $15.7 Million - $18.3 Million
241,676 Added 4.63%
5,466,667 $387 Million
Q1 2018

May 07, 2018

BUY
$72.84 - $88.8 $4.7 Million - $5.73 Million
64,494 Added 1.25%
5,224,991 $394 Million
Q4 2017

Jan 17, 2018

BUY
$71.15 - $83.52 $14.3 Million - $16.8 Million
201,109 Added 4.06%
5,160,497 $370 Million
Q3 2017

Nov 13, 2017

BUY
$72.11 - $85.47 $358 Million - $424 Million
4,959,388
4,959,388 $402 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.